StockNews.com Upgrades Ionis Pharmaceuticals (NASDAQ:IONS) to Hold

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday. A number of other brokerages also recently issued reports on IONS. Stifel Nicolaus increased their price objective on Ionis Pharmaceuticals from $45.00 to $50.00 and […]

Related Keywords

United States ,America ,Patrickr Oneil ,Raymond James ,Stifel Nicolaus ,Ionis Pharmaceuticals ,Bleakley Financial Group ,Victory Capital Management Inc ,Ionis Pharmaceuticals Company Profile ,Analyst Recommendations For Ionis Pharmaceuticals ,News Ratings For Ionis Pharmaceuticals Daily ,Xponance Inc ,Ionis Pharmaceuticals Stock Performance ,Nasdaq ,Institutional Trading Of Ionis Pharmaceuticals ,Ionis Pharmaceuticals Inc ,Securities Exchange Commission ,Goldman Sachs Group ,Morgan Stanley ,Get Free Report ,Exchange Commission ,Financial Advisors ,Financial Group ,North Carolina ,Victory Capital Management ,Capital Management ,Ionis Pharmaceuticals Daily ,Nasdaq Ions ,Lions ,Medical ,46433010 ,Upgrade ,Stocknews Com ,